Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the effect of givosiran on the pharmacokinetics of the 5-probe cocktail of midazolam, caffeine, losartan, omeprazole, and dextromethorphan, and their metabolites, in asymptomatic patients with Acute Intermittent Porphyria.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03505853
Study type Interventional
Source Alnylam Pharmaceuticals
Contact
Status Completed
Phase Phase 1
Start date April 26, 2018
Completion date January 10, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT05502133 - Identification of Acute Intermittent Porphyria Modifying Genes
Terminated NCT03547297 - INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Completed NCT01568554 - Clinical Diagnosis of Acute Porphyria